On December 30, 2025, iSpecimen Inc. signed an agreement to sell 6,875 shares of Series C Convertible Non-Voting Preferred Stock for $5.5 million, at $800 per share, convertible to common stock based on a specific formula. This is a significant event for the company as it opens up capital for future growth.